Navigation Links
Biomoda President Testifies Before New Mexico Legislature Supporting Clinical Funding for Early Lung Cancer
Date:10/2/2007

SANTA FE, N.M., Oct. 2 /PRNewswire-FirstCall/ -- John Cousins, President of Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com) of Albuquerque, NM, testified Monday before the New Mexico State Legislature's Interim Tobacco Settlement Committee in support of the lawmakers' $1.3 million proposal for funding a clinical study using the company's assay for early lung cancer detection.

The New Mexico legislature last year appropriated $350,000 to fund a clinical study that will begin later this year to screen veterans for lung cancer at its earliest stages. If approved, the $1.3 million funding proposal for 2008 would be a continuation of existing funding for the clinical study and will be considered during the state's 30-day legislative session beginning January 15, 2008.

"Members of the Tobacco Settlement Committee are at the forefront of funding essential studies to develop a nationwide screening protocol for lung cancer that ultimately will result in saving millions of lives," said Cousins. "We look forward to being part of this breakthrough effort and we are thrilled to be helping our veterans in this process. The men and women who served our country deserve the very best healthcare. This clinical work will provide just that."

Doug Craft, President of the Black Veterans Association of New Mexico, testified in support of Biomoda's efforts. "We are grateful for this opportunity and plan to work very hard to let our brothers and sisters who served in the military learn about, and be part of, this important opportunity that not only will further essential research, but also save lives."

Biomoda's technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope. The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

Contact: John Cousins (505) 821-0875


'/>"/>
SOURCE Biomoda, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Clintons new problem - Is the outgoing American president suffering from skin cancer?
2. Past President Narayanans Condition Still Critical
3. President and Founder of National Obesity Forum Resigns
4. President Bush Urges Citizens to Invest In Health Savings Account (HSAs)
5. President Bush proposes HSAs scheme for the benefit of both the workers and the country
6. President’s verdict: no need to panic over bird fl
7. Delhi Hospitals On Standby For President Bush
8. Former IMO President Shows Interest In Winning General Election
9. Chicken Dishes Were Off The Menu At Pakistan Presidents House
10. Man Appeals to President to Save His Ailing Son
11. President Kalam Meets Striking Medicos However Stir to Continue
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... Delaware farmer ... in St. Louis, Missouri. , Dickerson, of Laurel, farms about a thousand acres of ... beans, yellow squash on contract and pumpkins and other vegetables for the fresh market. ...
(Date:1/18/2017)... ... January 18, 2017 , ... Visually learn facts and tips ... antiperspirant, Certain Dri. , Excessive sweating and hyperhidrosis are common conditions that occur ... to explain the seven types of hyperhidrosis. This visual creates awareness about the ...
(Date:1/18/2017)... USA; and SHANGHAI, China – , ... ... -- Global public health organization NSF International has certified the ... to NSF/ANSI 53: Drinking Water Treatment Units – Health Effects, ... certification verifies that MicroCeramics’ NanoNose Pitcher Filter System filters the ...
(Date:1/18/2017)... ... , ... The V Foundation for Cancer Research, a top-rated cancer research charity, ... team, to compete in the Boston Marathon on April 17. From first-time participants ... annual marathon to join Team V and support the Foundation’s mission to declare victory ...
(Date:1/18/2017)... Fresno, CA (PRWEB) , ... January 18, 2017 ... ... is pleased to announce that their Vice President of Franchise Development, Paula Turner ... , This award-winning business program, which features the insights of top business leaders ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, ... products to treat a variety of dermatological diseases, ... compound DMT210, in a Phase 2 acne rosacea ... to downregulate the proinflammatory cytokines in the skin ... acne rosacea. This clinical trial, ...
(Date:1/18/2017)... de enero de 2017  Hoy, en el Foro ... una iniciativa global para avanzar el acceso a la ... países de renta baja y baja-media (LICs y LMICs). ... de crisis, particularmente en países de renta baja y ... de las muertes relacionadas con NCD. El objetivo de ...
(Date:1/18/2017)... 2017  With an annual growth ranging from 6% to 10%, South ... (Jakarta International Expo, March 22-24, 2017) serves the industry by fostering the regional discourse ... 2017? Investment Forum ASEAN -- ... Richer conference content Enhanced business matchmaking program Roadshows ... ...
Breaking Medicine Technology: